期刊文献+

Graves病患者合并胸腺增生的影响因素分析

Analysis of influencing factors in patients with Graves'disease complicated with thymic hyperplasia
下载PDF
导出
摘要 目的:分析Graves病患者合并胸腺增生的相关影响因素。方法:收集2018年11月—2020年11月临床确诊的Graves病患者100例,依据胸部CT结果分为两组:合并胸腺增生51例,未合并胸腺增生49例。分析两组年龄、病程、白细胞、中性粒细胞、肝功能、游离甲状腺功能(甲功)、促甲状腺素受体抗体(TRAb)、甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TGAb)等相关指标。结果:本研究中Graves病合并胸腺增生发生率为51%;Graves病合并胸腺增生组与未合并胸腺增生组相比,年龄较小,谷丙转氨酶(ALT)、FT3、FT4水平较高(t=-4.216,Z=-2.321、-2.837、2.633,均P<0.05);单因素Logistic回归分析结果提示,年龄、FT3、FT4均与Graves病合并胸腺增生相关(OR=0.942、1.046、1.040,95%CI:0.913~0.972、1.010~1.082、1.008~1.073,均P<0.05);多因素Logistic回归分析结果提示,年龄是评价Graves病合并胸腺增生的独立危险因素(OR=0.946,95%CI:0.917~0.977,P<0.05);年龄预测Graves病伴胸腺增生的受试者工作特征曲线(ROC曲线)下面积为0.734(95%CI:0.632~0.836),截断值为48.5岁,灵敏性72.5%,特异性75.5%(P<0.01)。结论:Graves病合并胸腺增生与TRAb水平无相关性,但与年龄呈负相关。 Objective:To analyze the related influencing factors in patients with Graves'disease complicated with thymic hyperplasia.Methods:A total of 100 patients with Graves'disease who were clinically diagnosed from November 2018 to November 2020 were enrolled in this study and divided into two groups based on chest CT findings:51 cases with thymic hyperplasia;49 cases without thymic hyperplasia.The age,course of disease,white blood cells,neutrophils,liver function,free thyroid function,TRAb,TGAb,TPOAb and other related indicators of the two groups of patients were analyzed.Results:In the study,the incidence of Graves'disease with thymic hyperplasia was 51%.Compared with the group without thymic hyperplasia,the age was younger in the group with thymic hyperplasia,while the ALT,FT3 and FT4 levels were higher,the difference was statistically significant(t=-4.216,Z=0.020,-2.837,2.633,all P<0.05).The univariate Logistic regression analysis showed that age of onset,FT3,FT4 were all related to Graves'disease with thymic hyperplasia(OR=0.942,1.046,1.040,95%CI:0.913-0.972,1.010-1.082,1.008-1.073,all P<0.05).The multivariate Logistic regression analysis showed that the age of onset was an independent risk factor for the evaluation of Graves'disease with thymic hyperplasia(OR=0.946,95%CI:0.917-0.977,P<0.05).The area under the ROC curve of age prediction of Graves'disease with thymic hyperplasia was 0.734(95%CI:0.632-0.836),the cut-off value was 48.5 years old,the sensitivity was 72.5%,the specificity was 75.5%(P<0.01).Conclusion:There is no relationship between thymic hyperplasia in patients with Graves'disease and TRAb level,but the age of onset is negatively correlated with thymic hyperplasia.
作者 肖金凤 刘艳静 张欣欣 何庆 XIAO Jin-feng;LIU Yan-jing;ZHANG Xin-xin;HE Qing(Department of Endocrinology and Metabolism,General Hospital,Tianjin Medical University,Tianjin 300052,China)
出处 《天津医科大学学报》 2022年第2期165-168,共4页 Journal of Tianjin Medical University
基金 天津市卫生健康委员会科技项目(ZC20210)。
关键词 GRAVES病 TRAB 胸腺增生 Graves'disease TRAb thymic hyperplasia
  • 相关文献

参考文献2

二级参考文献20

  • 1白耀.甲状腺病学-基础与临床[M].北京:科学技术文献出版社,2004.388.
  • 2Davies TF, Larsen PR. Thyrotixicosis// Larsen PR, Kronenberg HM, Melmed S. Wlilliams textbook of endocrinology. 10th ed. Philadelphia: Saunders, 2002: 374-424.
  • 3Chiovato L, Babesino G, Pinchera A. Graves disease//DeGroot LJ, Jameson JL. Endocrinology. 4th ed. Philadelphia: Saunders, 2001 : 1422-1449.
  • 4Greenspan FS. The thyroid gland//Greenspan FS, Gardner DG. Basic and clinical endocrinology. New York: Lange /McGraw- Hill, 2001: 201-272.
  • 5Fisher DA. Disorders of the thyroid in the newborn and infant// Sperling MA. Pediatric endocrinology. 2nd ed. Philadelphia: Sannders, 2002 : 161-186.
  • 6Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med, 2000, 160:1573-1575.
  • 7American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract, 2002,8:457-469.
  • 8Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006, 354:2783-2793.
  • 9Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid, 2003,13 : 3-126.
  • 10Cooper DS. Antithyroid drugs. N Engl J Med, 2005, 352:905- 917.

共引文献845

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部